BIOTECH News & Analysis

Fair value uneffected by suspended early-stage clinical trials.

Shares in this well-known ASX20 stock have tumbled in recent weeks, but is the market selloff overdone?  

First-half group net profit was driven lower by higher plasma collection costs.

Benchmark rebalance in June put pressure on some small-cap managers to get into the sector.

Morningstar looks at two diversified Chinese biotech names.

Are there still opportunities in the biotech sector now the covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager...

The single-product company is high-risk, high-reward.

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

These names from the Morningstar Exponential Technologies Index are trading at 4-star levels.